# Age-associated chemokine receptor expression profiles in human peripheral blood monocyte subsets predict cardiovascular disease risk

**Authors:** Ravi K. Komaravolu, Nandini Chatterjee, Sunil Kumar, Jessica L. Allen, Christopher Durant, Runpei Wu, Gabriel Valentin-Guillama, Chantel McSkimming, Fabrizio Drago, Angela M. Taylor, Yury I. Miller, Klaus Ley, Coleen A. McNamara, Ahmad Alimadadi, Catherine C. Hedrick

PMC · DOI: 10.3389/fimmu.2026.1749366 · Frontiers in Immunology · 2026-02-23

## TL;DR

This study shows how aging and heart disease affect immune cell receptors in blood, which could help predict cardiovascular risk.

## Contribution

The study identifies age- and disease-specific monocyte chemokine receptor profiles linked to CAD severity.

## Key findings

- Aging reduces anti-inflammatory classical monocytes and increases immature monocytes.
- CXCR3-expressing intermediate monocytes are elevated in severe CAD, independent of age.
- CCR6 expression on intermediate monocytes correlates with HDL cholesterol and CAD severity in older individuals.

## Abstract

Aging is a major contributor to chronic inflammation and coronary artery disease (CAD), yet how age influences monocyte chemokine receptor expression in relation to disease severity remains incompletely defined.

We performed high-dimensional single-cell antibody sequencing (Ab-Seq) of peripheral blood mononuclear cells from 61 participants (ages 42–78 years) enrolled in the Coronary Assessment of Virginia (CAVA) cohort. Aging was associated with remodeling of monocyte populations, including a reduction in anti-inflammatory classical monocytes and an expansion of immature monocytes. Among younger individuals with severe CAD, intermediate monocyte subcluster iMo_HLA-DRintCCR2low was increased, whereas anti-inflammatory classical monocyte cMo_CD33hiCD163hiCXCR4+ was reduced. In older individuals with progressive CAD, further reductions in CCR6+ and CXCR3+ classical monocytes were observed. Additional flow cytometry validation confirmed decreased CCR6-expressing classical monocytes in older individuals with high CAD burden. Independent of age, CXCR3-expressing intermediate monocytes were significantly increased in individuals with severe CAD. Transcriptomic analysis of CXCR3+ intermediate monocytes demonstrated increased expression of C1Q genes compared with CXCR3low cells. Interestingly, chemokine receptor expression also correlated with lipid parameters in older individuals where CCR6 expression on intermediate monocytes positively associated with HDL cholesterol and increased with CAD severity, whereas CXCR3 expression on classical monocytes declined with advancing CAD.

Aging is associated with distinct changes in monocyte chemokine receptor expression that relate to CAD severity. These findings identify age- and disease-associated monocyte immune features that may contribute to CAD progression.

## Linked entities

- **Genes:** C1qa (complement component 1, q subcomponent, alpha polypeptide) [NCBI Gene 12259], CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235], CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833]
- **Proteins:** CCR6 (C-C motif chemokine receptor 6), CXCR3 (C-X-C motif chemokine receptor 3)
- **Diseases:** coronary artery disease (MONDO:0005010), cardiovascular disease (MONDO:0004995)

## Full-text entities

- **Genes:** CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, C1QA (complement C1q A chain) [NCBI Gene 712] {aka C1QD1}, CXCL16 (C-X-C motif chemokine ligand 16) [NCBI Gene 58191] {aka CXCLG16, SR-PSOX, SRPSOX}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, C1QB (complement C1q B chain) [NCBI Gene 713] {aka C1QD2}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CD33 (CD33 molecule) [NCBI Gene 945] {aka CD33rSiglec, SIGLEC-3, SIGLEC3, p67}, IL32 (interleukin 32) [NCBI Gene 9235] {aka IL-32alpha, IL-32beta, IL-32delta, IL-32gamma, NK4, TAIF}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235] {aka BN-1, C-C CKR-6, CC-CKR-6, CCR-6, CD196, CKR-L3}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, CXCR5 (C-X-C motif chemokine receptor 5) [NCBI Gene 643] {aka BLR1, CD185, MDR15}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CD14 (CD14 molecule) [NCBI Gene 929], MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, CCR5 (C-C motif chemokine receptor 5) [NCBI Gene 1234] {aka CC-CKR-5, CCCKR5, CCR-5, CD195, CKR-5, CKR5}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, CCR4 (C-C motif chemokine receptor 4) [NCBI Gene 1233] {aka CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099}
- **Diseases:** cSVD (MESH:D059345), autoimmune diseases (MESH:D001327), vascular diseases (MESH:D014652), diabetes (MESH:D003920), FD (MESH:D000795), cardiovascular and cerebrovascular inflammation (MESH:D007249), immune dysregulation (OMIM:614878), cardiac pathologies (MESH:D006331), CAD (MESH:D003324), cardiovascular disease (MESH:D002318), CD (MESH:D003424), atherogenic (MESH:D050197)
- **Chemicals:** cholesterol (MESH:D002784), EDTA (MESH:D004492), PBS (MESH:D007854), DMSO (MESH:D004121), lipid (MESH:D008055), FcX (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** 1A-C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12970611/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12970611/full.md

## References

53 references — full list in the complete paper: https://tomesphere.com/paper/PMC12970611/full.md

---
Source: https://tomesphere.com/paper/PMC12970611